SCHEMBL7839017

SCHEMBL7839017

CC(C[C@H](O[Si](C)(C)C(C)(C)C)c1ccccc1)c1nc(C(=O)NN)c[nH]1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.34
NPSR1 Q6W5P4 7/20 0.34
ALDH1A1 P00352 5/20 0.34
RECQL P46063 4/20 0.34
POLB P06746 4/20 0.34
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
MAPK1 P28482 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
PAX8 Q06710 1/20 0.32
ROCK2 O75116 2/20 0.32
ROCK1 Q13464 2/20 0.32
ATM Q13315 2/20 0.31
P2RX7 Q99572 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7449607 0.90 MAPT (0.31) MAPTNPSR1ALDH1A1RECQLPOLB
SCHEMBL7452899 0.82 CA2 (0.30)
SCHEMBL7456315 0.78 SLC7A5 (0.35) KMT2AMEN1
SCHEMBL7446159 0.70 RIPK1 (0.37)
SCHEMBL7453038 0.69 BCAT2 (0.42) L3MBTL1ROCK2ROCK1
SCHEMBL7452060 0.67 MBTD1 (0.33) MAPTNPSR1ALDH1A1RECQLPOLB
SCHEMBL16263403 0.67 KCNA5 (0.42) MAPTALDH1A1KMT2AL3MBTL1ATM
SCHEMBL7451270 0.67 ADA (0.38) ALDH1A1KMT2A
SCHEMBL6525612 0.67 ATM (0.39) MAPTALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL13871075 0.66 RIPK1 (0.39) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098885-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-16 EP disclosed
WO-2000005217-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-02-03 WO disclosed